Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Anika Therapeutics Inc
ANIK
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$21.27
-0.15
-0.7%
Ult. Agg.: Oct 26, 8:11 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 11 giorni da adesso in ven nov 6th, prima dell'apertura del mercato
Anika Therapeutics Financials
Anika Therapeutics (ANIK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Anika Therapeutics Raises FY2026 Sales Guidance from $114.000M-$122.500M to $118.460M-$124.101M vs $118.612M Est
Anika Therapeutics (NASDAQ:ANIK) raises FY2026 sales outlook from $114.000 million-$122.500 million to $118.460 million-$124.101 million vs $118.612 million estimate.
Benzinga Newsdesk
PRO
Anika Therapeutics Q2 Adj. EPS $0.42 May Not Compare To $(0.08) Estimate, Sales $32.610M Beat $29.215M Estimate
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
PRO
Anika Therapeutics Affirms FY2026 Sales Guidance of $114.000M-$122.500M vs $117.220M Est
Anika Therapeutics (NASDAQ:ANIK) affirms FY2026 sales outlook from $114.000 million-$122.500 million to $114.000 million-$122.500 million vs $117.220 million estimate.
Benzinga Newsdesk
PRO
Anika Therapeutics Q1 Adj. EPS $0.27 Beats $(0.16) Estimate, Sales $29.612M Beat $28.142M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.16) by 268.75 percent. This is a 550 percent increase over losses of $(0.06) per share from
Benzinga Newsdesk
Insights into Anika Therapeutics Q4 Earnings
Benzinga Insights
